Navigation Links
Signalife Announces Webcast

GREENVILLE, S.C., April 11 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has confirmed that it has filed its form 10-KSB, and the company's Chairman and Chief Executive Officer, Dr. Lowell T. Harmison, has scheduled a webcast on April 14, 2008, at 10:00 a.m. EDT.

Dr. Harmison stated: "Now that Signalife has closed filing the company's form 10-KSB and the Company is manufacturing and shipping product, I am pleased to provide direction on new contracts, pending orders and production, various product initiatives (from the Fidelity 100 to the prospective industry-wide application of the Fidelity 1000 module), and the Athletes For Life partnership, as well as such issues as the Company's immediate, positive financial prospects as well as several other initiatives that have now been completed. The webcast will be broadcast from a studio and will be attended by representatives of Athletes for Life Foundation and selected invited members of the business press. To the extent time permits, I will answer questions following my presentation. I urge all persons following the company to view the webcast."

You may access the webcast either directly at, or through Signalife's webpage at, and will have the opportunity to submit written questions over the internet. You may also view or review the webcast for a 12-month period at the same website addresses (please allow several hours for Signalife to effectuate this archival link). All individuals viewing the original webcast or any replay are reminded that the webcast is copyrighted by the company and cannot be recorded or rebroadcast without the company's express written consent.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
2. Signalife Sees Accretive Purchase and Financial Commitments
3. Signalife Wins Second Frost & Sullivan Technology Award
4. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
5. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
6. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
7. U.S. Patent 7,299,083 Awarded to Signalife
8. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
9. Signalife Continues to Procure Purchase Orders, Revenues
10. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
11. Signalife Receives Another $3.3 Million Sales Orders
Post Your Comments:
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
(Date:11/24/2015)... 2015  Twist Bioscience, a company focused on ... Twist Bioscience chief executive officer, will present at ... 1, 2015 at 3:10 p.m. Eastern Time at The Lotte ... --> --> About ... is on Twitter. Sign up to follow our ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW Telbec/ - ProMetic Life ... announced today that Mr. Pierre Laurin , President and ... presentation at the upcoming Piper Jaffray 27 th Annual ... Hotel, on December 1-2, 2015. st , ... for one-on-one meetings throughout the day. The presentation will be ...
(Date:11/24/2015)... YORK , November 24, 2015 ... in a European healthcare ... which the companies will work closely together in identifying European ... unmet medical need. The collaboration is underpinned by a significant ... fund. This is the first investment by Bristol-Myers Squibb in ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
Breaking Biology News(10 mins):